Magazine Article | February 1, 2023

Companies To Watch: Corner Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Corner Therapeutics is in early development of dendritic cell hyperactivators (hDC), seeking to fill in a large gap in cancer immunotherapy: lack of sufficient memory T cells to attack and defend against tumors over patients’ lifetimes. Corner’s hDC therapy would require small biopsies to capture cancer antigens from each patient for the hyperactivated dendritic T cells to target. The treatment would achieve the long sought-after goal of a cancer vaccine, inducing durable immunity, and future applications could possibly extend to infectious diseases as well.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader